Ke Gao
Urology researcher at Xi'an People's Hospital and first author of a 2026 multicentre study showing that the fat content of TSC kidney tumours predicts how well they shrink on everolimus
Department of Urology, Xi'an People's Hospital (Xi'an Fourth Hospital), Northwest University · also listed at the State Key Laboratory of Cancer Biology, Air Force Medical University, Xi'an (2026)
Tuberous sclerosis complex (TSC) is a genetic disease in which the brake on mTORC1, the cell's growth-control complex, is missing. One result is angiomyolipoma, a benign kidney tumour made of blood vessels, smooth muscle and fat that can grow large and bleed. Everolimus, a drug that blocks mTORC1, is the standard medical treatment. Ke Gao is first author of a prospective study from several Chinese hospitals that followed 183 patients with these tumours (GAO2026B).
Everolimus cut tumour volume by half or more in 44% of patients after 3 months and in 83% after 6 months. Tumours with little fat shrank better than fat-rich ones, which makes sense if the drug acts mainly on the growing muscle and vessel cells rather than on the fat. A lower dose seemed to work about as well and caused fewer mouth ulcers, but that comparison was exploratory and not randomised, so it needs a proper trial. Tumours grew back when treatment stopped.
On PubMed, Gao's other recent papers come from the same urology department at Xi'an People's Hospital, part of Northwest University's School of Medicine. They include a 2025 rat study on how a high-salt diet raises blood pressure and cholesterol through the immune signal IL-17, and a 2026 review on gut bacteria in cachexia, the wasting syndrome of cancer, written with the State Key Laboratory of Cancer Biology at the Air Force Medical University. No personal institutional page was found, so the position shown is the one on the papers.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2026 | H | Tumor fat composition predicts response to everolimus and supports low-dose therapy in TSC-associated renal angiomyolipomas: a multicenter prospective study GAO2026B First author of the multicentre prospective cohort of 183 patients, which linked lower tumour fat content to a better response to everolimus. |
Co-authors in the Atlas 1
People with a profile here who share at least one study with Ke Gao.
ShowHide
- Jianxin Ni Urologist at Xi'an People's Hospital and senior author of a 2026 multicentre study of everolimus for TSC kidney tumours, with further work on prostate cancer
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.